Objectives: The role of radiotherapy (RT) in locally advanced pancreatic cancer (LAPC) is uncertain. This study examines patterns of care and survival outcomes of LAPC undergoing chemotherapy alone versus chemotherapy plus RT (C + RT).
P
ancreatic adenocarcinoma is the fourth leading cause of cancer death in the United States. 1 At the time of diagnosis, approximately 30% present with locally advanced pancreatic cancer (LAPC). 2 For LAPC, current National Comprehensive Cancer Network guidelines suggest chemotherapy or chemotherapy with radiation (RT) in select patients without systemic disease and good performance scores. 3 Median survival for these patients is poor, ranging from 6 to 11 months. 4 Presently, the benefit of adding RT to chemotherapy (C + RT) to improve survival for LAPC is uncertain. [4] [5] [6] Although current data demonstrating a survival benefit of RT is mixed, studies have shown improvements in local control with the addition of RT, especially with modern day RT techniques, translating into improved quality of life by reducing localized pain and symptoms related to tumor obstruction. 7, 8 Furthermore, approximately 30% of patients with pancreatic cancer die with locally destructive disease as a component of their disease, contradicting the historical belief that all pancreatic cancer cases die from metastatic disease. 9 Radiotherapy may therefore play a major role for these patients who progress locally. In this population-based analysis, we queried the National Cancer Database (NCDB) to evaluate patterns of care and survival outcomes between C + RT compared with chemotherapy alone to assess whether there is a survival improvement with the addition of RT to chemotherapy in LAPC patients.
MATERIALS AND METHODS

Data Source and Patient Selection
The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. It is a hospital-based registry that represents 70% of all cancer cases in the United States, drawing data from more than 1500 commission-accredited cancer programs. 10 The data used in the study are derived from a de-identified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data.
We identified 356,108 patients aged 18 years and above with pancreatic cancer diagnosed between 2003 and 2011. This data set was then limited to inoperable patients who had treatment with chemotherapy with or without RT, excluding those with unknown vital status, unknown tumor (T)-and nodal (N)-stage, M1 disease, and those undergoing surgery. The resulting 34,057 patients were then limited to adenocarcinoma histologic codes [International Classification of Disease for Oncology (third edition) histology code 8140-41, 8255, 8260-61, 8310, 8323, and 8440]. This left a total of 19,685 patients receiving chemotherapy alone or chemotherapy with RT (C + RT). Next, to avoid selection bias, the start of RT was within 0 to 6 months of the chemotherapy start date; others outside this range were excluded (n = 1464). We then excluded palliative cases (n = 4526), an available category in the NCDB distinguishing treatment modality given for curative intent versus the same modality being used for palliation, based on prior NCDB analyses, leaving 13,695 cases for analysis.
on the American Joint Committee on Cancer staging guidelines.
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Distance to treatment facility was analyzed as a categorical variable, using the median as a cutoff. Chemotherapy was categorized in the NCDB as single-agent, multi-agent, or not otherwise specified (NOS). Cancer antigen (CA) 19-9 was not included as these data were not recorded for the majority of cases. Three-dimensional (3D) and intensity-modulated radiotherapy (IMRT) are coded for a subset of patients in the NCDB. A minimum RT dose was not selected as an inclusion criteria because all cases included were coded as curative intent; however, a subgroup analysis was performed for those who had received a complete course of RT. A complete course of RTwas defined as 45 to 54 Gy based on National Comprehensive Cancer Network guideline recommendations. 12 
Statistical Analysis
All statistical analyses were performed using SPSS V23.0 (SPSS Inc, Chicago, Ill). Pearson χ 2 tests were used to assess associations between categorical variables and treatment group. Similar to previous database analyses, survival analysis in this study excluded patients dying within the first 1 month of diagnosis in an effort to conservatively reduce the probability of type I error due to selection and immortal-time biases, where earlyoccurring deaths may be categorically attributed to the no-RT cohort 13, 14 ; overall survival (OS) was first examined using the Kaplan-Meier method. Univariate survival analysis was performed with the log-rank test, with Cox proportional hazards regression used to estimate hazard ratios (HRs). Multivariate Cox regression analysis (MVA) was performed using OS as outcomes; all tests were 2-sided with a 0.05 level of significance. Patient, clinical, and treatment variables were selected a priori. Multiple binary logistic regression models were used to assess the association between variables included and treatment modality. HosmerLemeshow test was used to check for the goodness-of-fit of the regression models.
To further address confounding variables, propensity score matching (PSM) was performed for patients treated with C + RT or chemotherapy alone accounting for the following variables: age, gender, race, insurance status, residence, comorbidity score, facility type, distance to hospital (miles), year of diagnosis, T-stage, N-stage, and chemotherapy (single agent, multi-agent, NOS). The propensity score was calculated using logistic regression to estimate the probability of receiving C + RT versus chemotherapy alone. One-to-one propensity matching without replacement was performed using caliper match algorithm described by CocaPerraillon, 15 with the caliper width set to 0.05 times the standard deviation of the logit of the propensity score. 16 These outcomes were assessed using a log-rank test, and the HR was determined by univariate Cox regression. The score calculation was blinded with respect to patient outcomes.
Subgroup analyses including the same variables used in the Cox regression model for the entire cohort was performed for the following: (1) patients starting RT 3 to 6 months after the chemotherapy start date to evaluate survival outcomes after a period of induction therapy, (2) patients receiving a complete course of RT (45-54 Gy), (3) those treated in more recent years (2008-2011), (4) T4 disease, and (5) patients coded as 3D RT (n = 1043), IMRT (n = 1641) versus chemotherapy alone (n = 5306) to assess for survival outcomes by RT modality.
RESULTS
Patient Characteristics
A total of 13,695 patients were included: 5306 (38.7%) underwent chemotherapy alone, 8389 (61.3%) received C + RT.
Median follow-up for all patients was 10.2 months (range, 1.0-120.3 mo). Median follow-up for the chemotherapy alone group was 9.2 months (range, 1.0-120.3 mo); median follow-up for the C + RT group was 10.8 months (range, 1.0-114.0 mo). Patient and treatment characteristics are presented in Table 1 .
Patterns of Care
From 2003 to 2011, the use of C + RT in LAPC steadily declined in contrast with the use of chemotherapy alone, which gradually increased (Fig. 1A) . In 2003, 73% of patients underwent C + RT compared with 27% for chemotherapy alone; in 2011, C + RT was 53.3% compared with 46.7% for chemotherapy alone. For the subset of patients recorded as receiving 3D RT (n = 1043) or IMRT (n = 1641), use of IMRT increased from 2003 in contrast with 3D RT, which declined (Fig. 1B) . In 2003, 27.1% were treated with IMRT compared with 72.9% with 3D RT; in 2011, 72.4% of cases were treated with IMRT compared with 27.6% with 3D RT.
Factors Associated With Treatment Selection
In a binary multiple logistic regression model that adjusted for patient and treatment demographics (Supplemental Table 1 , http://links.lww.com/MPA/A599), patients treated with chemotherapy alone, compared with C + RT, were more commonly patients aged 65 years and above [odds ratio (OR), 0.78; 95% confidence interval (CI), 0.71-0.85; P < 0.001], female sex (OR, 0.93; 95% CI, 0.87-1.00; P = 0.057), uninsured (OR, 0.74; 95% CI, 0.60-0.91; P = 0.005), treated at comprehensive community (OR, 0.82; 95% CI, 0.72-0.95; P = 0.008) or academic/research hospitals (OR, 0.69; 95% CI, 0.60-0.80; P < 0.001), lived further than 12 miles from the hospital (OR, 0.89; 95% CI, 0.82-0.96; P = 0.003), had higher comorbidity scores (OR, 0.91; 95% CI, 0.84-0.98; P = 0.017), and more often presented with node positive disease (OR, 0.85; 95% CI, 0.79-0.92; P < 0.001). In contrast, patients treated with C + RT were more commonly in urban (OR, 1.39; 95% CI, 1.25-1.55; P < 0.001) or rural locations (OR, 1.83; 95% CI, 1.41-2.37; P < 0.001). There were statistically significantly lower odds of receiving RT in the more recent years from 2004 onward (ORs, 0.42-0.68; P < 0.001).
Predictors for OS
Unadjusted 1-year OS was longer for C + RT versus chemotherapy alone (45.6% vs 38.7%), as was 2-year OS (12.9% vs 11.9%) (HR, 0.88; 95% CI 0.85-0.91; P < 0.001) ( Fig. 2A) . Based on MVA, the C + RT was associated with an improved OS (HR, 0.84; 95% CI, 0.81-0.87; P < 0.001). Additional predictors correlating with longer OS under MVA included black race (HR, 0.93; 95% CI, 0.88-0.98; P = 0.006) and other race (HR, 0.87; 95% CI, 0.79-0.97; P = 0.011), primary treatment in an academic/research hospital (HR, 0.93; 95% CI, 0.86-1.00; P = 0.038), treatment in more recent years (2009-2011) (HR, 0.81-0.85; P < 0.001), and multi-agent chemotherapy (HR, 0.74; 95% CI, 0.72-0.77; P < 0.001). On MVA, variables associated with worse OS included older age (HR, 1.09; 95% CI, 1.04-1.14; P < 0.001), urban (HR, 1.08; 95% CI, 1.03-1.14; P = 0.004) or rural residence (HR, 1.17; 95% CI, 1.04-1.32; P = 0.011), having government-type insurance (HR, 1.07; 95% CI, 1.02-1.12; P = 0.010) or no insurance (HR, 1.16; 95% CI, 1.04-1.30; P = 0.008), Charlson comorbidity score greater than or equal to 1 (HR, 1.09; 95% CI, 1.05-1.14; P < 0.001), T2 (HR, 1.09; 95% CI, 1.02-1.29; P = 0.018) or T3 disease (HR, 1.12; 95% CI, 1.00-1.25; (Continued on next page) P = 0.044), and node positive disease (HR, 1.09; 95% CI, 1.06-1.14; P < 0.001) ( Table 2) . We next compared survival outcomes by RT modality (3D RT vs IMRT). Median follow-up for 3D RT versus IMRT is 10.58 and 11.47 months, respectively. On subgroup analysis comparing C + IMRT, C + 3D RT, and chemotherapy alone, unadjusted 1-year OS was 49.1%, 45.1%, and 38.7% respectively; 2-year OS was 13.1%, 11.6%, and 11.9% accordingly (Fig. 2B) . Under MVA, C + 3D RT (HR, 0.86; 95% CI, 0.80-0.92; P < 0.001) and C + IMRT (HR, 0.81; 95% CI, 0.77-0.86; P < 0.001) were associated with a statistically significant improvement in OS (Supplemental Table 2 , http://links.lww. com/MPA/A599).
Propensity Score Matching
Propensity score matching for all patients combined resulted in well-matched comparison groups between chemotherapy alone, C + 3D RT, and C + IMRT. Consistent with the results from MVA, patients receiving C + RT had longer 1-year (47.2% vs 38.4%) and 2-year OS (13.0% vs 11.9%) (HR, 0.86; 95% CI, 0.82-0.89; P < 0.001). Further analysis demonstrated patients receiving IMRT versus chemotherapy alone had longer 1-year (49.0% vs 37.8%) and 2-year OS (13.1% vs 10.8%) (HR, 0.80; 95% CI, 0.75-0.86; P < 0.001) (Fig. 3A) . Inconsistent with MVA, patients receiving 3D RT did not have a statistically significant longer 1-year (45.2% vs 39.5%) or 2-year OS (11.6% vs 12.4%) (HR, 0.92; 95% CI, 0.84-1.03; P = 0.060) when compared with chemotherapy alone (Fig. 3B) . When comparing survival outcomes between IMRT and 3D RT, IMRT was associated with improved 1-year (50.6% vs 44.7%) and 2-year OS (13.9% vs 11.6%) (HR, 0.86; 95% CI, 0.78-0.95; P = 0.002) (Fig. 3C) .
DISCUSSION
Utilization of RT in LAPC appears to be decreasing, whereas the rate of chemotherapy alone is increasing in this populationbased analysis. Specifically, the use of C + RT declined from 2003 to 2011 (73%-53%), whereas the rate of chemotherapy alone increased. Of those receiving RT, rates of IMRT increased (27%-72%), whereas 3D RT decreased (73%-28%). Use of C + RT also correlated with patients' age, sex, insurance status, treatment facility, distance to the hospital, residence, and having node positive disease, consistent with other study findings. 17 Lastly, the addition of RT appeared to be associated with a modest improvement in survival, in particular for those receiving IMRT. Several events may be contributing to the decrease in RT use. 19 Improved chemotherapy regimens including FOLFIRINOX (leucovorin, fluorouracil , irinotecan, oxaliplatin) and gemcitabine/nab-paclitaxel may also contribute to the downtrend in RT use because these regimens have demonstrated significantly better response rates when compared with gemcitabine alone. 20 Whereas the majority of pancreatic cancer patients die of systemic disease, a substantial portion progress and die of local disease, suggesting the importance of local treatment modalities including RT. 9 Furthermore, local progression can cause pain and obstruction, translating into worse quality of life outcomes. Early studies published in the 1980s comparing chemotherapy with C + RT, using split course RT with older techniques, demonstrated mixed results. 21, 22 More recent studies including the French trial (FFCD-SFRO), which randomized LAPC to gemcitabine alone versus high-dose RT (60 Gy) with concurrent 5-fluorouracil and cisplatin followed by gemcitabine, found increased toxicity in the C + RT arm and worse survival outcomes when compared with the gemcitabine alone arm (median survival 8.6 vs 13.0 mo; P = 0.03). 19 In contrast, the subsequent European Cooperative Oncology Group (ECOG) study, comparing gemcitabine alone versus gemcitabine plus RT (50.4 Gy) in LAPC, found C + RT improved OS (9.2 vs 11.0 mo; P = 0.017). 4 Both trials lacked RT quality assurance measures. This brings us to the phase III LAP 07 trial, which evaluated the use of gemcitabine alone versus gemcitabine followed by RT. 6 Radiotherapy quality assurance was available. At a median follow-up of 36 months, OS was not significantly different between chemotherapy alone and C + RT.
Many of these prior trials applied older RT techniques without significant quality measures in place. Even the LAP 07 trial, which had quality measures in place, used conventional RT techniques that may have reduced the impact of the local therapy in these patients given dose constraints of surrounding organs at risk. 6 Data presented in this NCDB analysis suggest that patients who undergo RT may benefit more from advanced RT techniques such as IMRT, particularly when abdominal RT can be associated with significant toxicity. Whereas the results in our study demonstrate only a modest improvement in OS with C + RT, the OS improvement is only appreciated in patients undergoing IMRT, suggesting that reasonable candidates for RT should be offered IMRT over 3D planning. The slight absolute survival benefit with the addition of RT must be weighed with the risk of additional RT toxicity, especially with 3D modality treatment. Decision for additional RT in this setting ought to be personalized to each patient based on their performance status, comorbidities, disease status, and goals of care.
Lack of RT central quality control is a major criticism in prior pancreatic cancer trials that have demonstrated deleterious effects of RT, including the ESPAC-1 trial, which compared adjuvant chemotherapy with CRT in resected pancreatic cancer. 18, 23 A meta-analysis of 8 cooperative group clinical trials [including Radiation Therapy Oncology Group (RTOG) 9704: adjuvant CRT + 5-fluorouracil vs CRT + gemcitabine] demonstrated a significant association between RT quality deviation and detriment in OS (HR, 1.74), further emphasizing the importance of quality control and RT technique. 24, 25 This has led to stricter RT contouring guidelines and centralized review in the current protocols including RTOG 0848 and 1201. 26, 27 The RTOG 0848 study is evaluating the benefit of adjuvant CRT in resectable pancreatic cancer. The RTOG 1201 is a phase II randomized trial comparing standard (50.4 Gy) or high-dose (63.0 Gy) RT with gemcitabine and nab-paclitaxel to gemcitabine and nab-paclitaxel alone for unresectable pancreatic cancer. Both cooperative group trials incorporate the requirement for strict adherence (via rapid central review) to contouring guidelines and treatment planning. Intensity-modulated radiotherapy is allowed in both trials and mandated in the high-dose arm of RTOG 1201.
Whereas C + RT has been a component of therapy for LAPC since the early studies in the 1980s, there have been many recent advances including improvements in chemotherapy agents, newer RT techniques such as IMRT, and better knowledge of the underlying molecular biology. There have been several recent advances for example, including use of multi-agent chemotherapy regimens for LAPC. 20 In a phase III trial comparing FOLFIRINOX with gemcitabine alone, FOLFIRINOX had an improved median OS of 11.1 versus 6.8 months (HR, 0.57; P < 0.001). 28 Whereas the majority of patients in this NCDB analysis were treated with single-agent chemotherapy and before the published phase III trials, results demonstrating OS improvement with multi-agent chemotherapy were consistent with the phase III data. Improvements in distant disease control may make the role of local therapy even more important in LAPC patients who do not progress on systemic induction therapy.
The NCDB confers several benefits over other population databases, including a large sample size and the availability of treatment details including receipt of chemotherapy. However, the NCDB is limited by its retrospective nature and the potential for miscoding. There is also inherent selection bias by treatment modality, which we attempt to account for in MVA and PSM analyses. Cancer antigen (CA) 19-9 was not available for the majority of patients. Proper staging during the study time period is also an issue, as staging workup including the use of endoscopic ultrasound, varied by institution. A large proportion of patients in this study were considered unresectable with T1-3 stage; we attempted to address this by performing a subgroup analysis of only T4 tumors. Information on chemotherapy agent, dose, and number of cycles administered was unknown. Restaging is not recorded in the NCDB; as such, patients in the chemotherapy alone arm may have had progressive disease preventing them from receiving RT, which would not have been recorded. To account for this, we performed a subset analysis including patients alive after 3 months of induction chemotherapy, who were subsequently treated with RT or additional chemotherapy. Additionally, RT modality including 3D RT and IMRT is not coded for all patients and therefore could only be analyzed for a subset of individuals. Data on RT modality in the NCDB are reported broadly, with a large proportion of patients coded as receiving a particular photon energy, but not specifying planning modality (3D RT vs IMRT), which contributed to those excluded from subgroup analyses. It may be that patterns of coding between photon energies and modality could contribute somewhat to the increased utilization of IMRT found in our study. However, our findings are consistent with other studies showing increased use of IMRT in gastrointestinal malignancies including pancreatic cancer. 29 Lastly, outcome measurements are limited to OS because the NCDB does not record data on locoregional control, distant disease, cancer-specific survival, or symptom control, which would have been a valuable endpoint in this study.
Published randomized data on the efficacy of RT with chemotherapy in LAPC continue to remain inconclusive. This may be owing to insufficient RT doses and older techniques used in the past, suboptimal chemotherapy regimens to control systemic disease or increase radiosensitization, or inherent radioresistance of pancreatic cancer. Based on data presented in this study, use of RT for LAPC continues to decline in the United States. For patients who are good candidates for C + RT, consideration should be given to the use of IMRT over 3D RT given results from this population-based analysis. Randomized controlled trials including 
